SEQUENTIAL CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE & IFOSFAM

本研究的目的是评估两个周期的大剂量化疗的可行性（依托泊苷、顺铂和环磷酰胺），然后（异环磷酰胺、卡铂和紫杉醇）各自联合G-CSF（粒细胞集落刺激因子）和自体干细胞回输给晚期恶性肿瘤患者，以评估这种方案的毒性，并确定在该联合高剂量方案中可输送的紫杉醇的最大耐受剂量。医师资格总结：经组织学证实诊断为乳腺癌、卵巢癌、软组织肉瘤、恶性黑色素瘤、骨肉瘤、尤因氏肉瘤、肾母细胞瘤、胃肠道恶性肿瘤或小细胞癌;患者必须接受手术，无疾病证据，或必须在任何化疗、放疗或免疫治疗方案下有完全缓解或部分缓解;生理年龄大于或等于18岁且小于或等于55岁;必须达到或超过80%的Karnofsky性能状态（患者可以努力进行正常活动，有一些疾病体征或症状）。

The objectives of this study are to evaluate the feasibility of administering two cycles of high dose chemotherapy (etoposide, cisplatin and cyclophosphamide) followed by (ifosfamide, carboplatin and taxol) each combined with G-CSF (Granulocyte Colony Stimulating Factor) and autologous stem cell reinfusion to patients with advanced malignancies, to evaluate the toxicities of such a regimen, and to define the maximum tolerated dose of taxol deliverable in this combined high dose regimen. Physician Eligibility Summary: Histologically proven diagnosis of Breast Cancer, ovarian Cancer, Soft Tissue Sarcoma, Malignant Melanoma, Osteosarcoma, Ewings's Sarcoma, Wilm's Tumor, Gastrointestinal Malignancies, or Small Cell Carcinoma; Patient must be surgically with No Evidence of Disease or must have had a Complete Response or Partial Response on any chemotherapeutic, radiotherapeutic, or immunotherapeutic regimen; Physiologic age greater than or equal to 18 and less than or equal to 55; Must meet or exceed a Karnofsky Performance Status of 80% (Patient can carry on normal activity with effort, some signs or symptoms of disease).